Table 3 Characteristics of patients with non-metastatic LAPA at restaging, according to the delivered treatment, CRT, or continued chemotherapy (n = 187)

Mean age + SD

66.1 ± 9.85

71.4 + 9.97

< 0.01

Performance status^a(%) ≥ 2

7 (5.6)

8 (13)

0.089

Mean BMI + SD

23.1 ± 3.77

23.2 ± 4.78

0.89

Weight loss > 5% body weight^a(%)

92 (73)

42 (69)

0.55

Diabetes (%)

19 (15)

8 (13)

0.72

Back pain^a(%)

88 (70%)

38 (62%)

0.3

Serum CA 19–9 level^a(IU) (range)

2180 ± 5718

1886 ± 4785

0.74

 Head

82 (65)

43 (70)

0.46

 Body

36 (29)

16 (26)

0.66

 Tail

8 (6.3)

2 (3.3)

0.5

Arterial invasion^a(%)

63 (50)

21 (34)

0.045

 FOLFIRINOX

29

 Gemcitabine

32

 5 FU

126

Mean number of cycles after restaging (range)

 Grade ≥ 3

7 (5.5)

15 (25)

< 0.01

 Neutropenia

10 (8)

20 (33)

< 0.01

 Diarrhoea

6 (5)

4 (7)

Ns

 Polyneuropathy

0

10 (16)

< 0.01